Value of Comorbidity Scales for Predicting Survival After Radiochemotherapy of Small Cell Lung Cancer

Lukas Kaesmann, Stefan Janssen, Steven E. Schild, Dirk Rades

Research output: Contribution to journalArticle

8 Scopus citations


The Charlson Comorbidity Index plus three comorbidity scales were evaluated for survival after radiochemotherapy of limited stage SCLC. For the Charlson Comorbidity Index, 2–4 points were compared to 5–8 points. For the Age-Comorbidity Score, 2–6 points were compared to 7–10 points. For the Medical Research Council (MRC) Breathlessness Scale, grades 0–2 were compared to grades 3–5. For the Simplified Comorbidity Score, 0–5 points were compared to 6–11 and 12–17 points. Charlson Comorbidity Index (p = 0.022) and MRC Breathlessness Scale (p 

Original languageEnglish (US)
Pages (from-to)295-298
Number of pages4
Issue number2
StatePublished - Apr 1 2016



  • Charlson Comorbidity Index
  • MRC Breathlessness Scale
  • Radiochemotherapy
  • Small cell lung cancer
  • Survival prognosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this